Combining genome-engineered CAR-T cells and innate immune agonists for the treatment of gastrointestinal malignancies
CAR-T cells are engineered immune cells designed to specifically target and destroy cancer cells. While they have shown great success in treating blood cancer, they face significant challenges in solid tumors. These challenges include limited penetration into the tumor and functional suppression by the tumor microenvironment. In this project, the researchers combine CAR-T cells with agents that stimulate the innate immune system, which could enhance the efficacy of CAR-T cells in solid tumor settings.